Select Language
Complement C5
Complement C5 Overview
| English Name | Complement C5 | Approved Drugs | 8 |
| Drugs in Clinical Trials | 19 | Target Synonym | C5a，Complement Component 5，ECLZB，Anaphylatoxin C5a Analog，C5a Anaphylatoxin，C5b，C5，Prepro-C5，CPAMD4，Complement C5，C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4，C5D |
| Highest Development Stage | Approved | ||
| English Name | Complement C5 |
| Target Synonym | C5a，Complement Component 5，ECLZB，Anaphylatoxin C5a Analog，C5a Anaphylatoxin，C5b，C5，Prepro-C5，CPAMD4，Complement C5，C3 And PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 4，C5D |
| Approved Drugs | 8 |
| Drugs in Clinical Trials | 19 |
| Highest Development Stage | Approved |
Complement C5 Product List
- Product Category
Protein (11)Kits (1)
- Product Status
Launched (12)
- Species
Human (6)Mouse (1)Rat (2)Cynomolgus (2)Rabbit (1)
- Tag
His Tag (7)His Tag & Avi Tag (3)Fc Tag (1)- (1)
- Conjugate
Unconjugated (8)Biotin-labeled (3)- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CO5-H52Ha |  Human | HEK293 | Human Complement C5 Protein, His Tag, low endotoxin (MALS verified) |  |  |  |
HOT CO5-H82E9 | Human | HEK293 | Biotinylated Human Complement C5 Protein, His,Avitag™ (MALS verified) |  | | |
HOT CO5-M52H4 |  Mouse | HEK293 | Mouse Complement C5 Protein, His Tag |  | | |
HOT CO5-R52H5 |  Rat | HEK293 | Rat Complement C5 Protein, His Tag |  | | |
CEA-B241 | Human | - | Human Complement C5 ELISA Kit | |||
CO5-H5253 | Human | HEK293 | Human Complement C5 Protein, Fc Tag |  | | |
CO5-H52H7 | Human | HEK293 | Human Complement C5 (w917s) Protein, His Tag (MALS verified) |  | | |
CO5-H52Hx | Human | HEK293 | Human Complement C5 (R885H) Protein, His Tag |  | | |
CO5-C52Hx |  Cynomolgus | HEK293 | Cynomolgus Complement C5 Protein, His Tag (MALS verified) |  | | |
CO5-C82E3 | Cynomolgus | HEK293 | Biotinylated Cynomolgus Complement C5 Protein, His,Avitag™ (MALS verified) |  | | |
Total: 12
- 1
- 2
Complement C5 Background
Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with C5AR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.
Complement C5 Synonyms
Complement C5,C5,CPAMD4
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Eculizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Hemoglobinuria, Paroxysmal | Details | |
| Eculizumab biosimilar (IBC GENERIUM) | Phase 3 Clinical | Ibc Generium | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details | |
| Gefurulimab | TPP-2511; ALXN-1720; CON-9978 | Phase 3 Clinical | Alexion Pharmaceuticals Inc | Myasthenia Gravis; Proteinuria | Details |
| Eculizumab biosimilar (Biocad) | BCD-148 | Phase 3 Clinical | BIOCAD JSC | Hemoglobinuria, Paroxysmal | Details |
| Cemdisiran | ALN-CC5; AD-62643; ALN-62643; L96 | Phase 3 Clinical | Alnylam Pharmaceuticals Inc | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Myositis; Atypical Hemolytic Uremic Syndrome; Myositis, Inclusion Body; Geographic Atrophy; Macular Degeneration | Details |
| Nomacopan | EV-576; rEV-576; rVA576 | Phase 3 Clinical | Evolutec | Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Conjunctivitis, Allergic; Pemphigoid, Bullous; Geographic Atrophy | Details |
| Tesidolumab | NOV-4; LFG-316 | Phase 2 Clinical | Novartis Pharma Ag, Morphosys Ag | Rejection of renal transplantation; Uveitis, Intermediate; Hemoglobinuria, Paroxysmal; Wet Macular Degeneration; Geographic Atrophy; Uveitis, Posterior; Panuveitis; Macular Degeneration | Details |
| OCUL-101 | OCUL101 | Phase 2 Clinical | Diabetic macular oedema; Geographic Atrophy; Retinal Neovascularization; Macular Degeneration | Details | |
| KRIYA-825 | KRIYA-825; VV-14295 | Phase 2 Clinical | Kriya Therapeutics Inc | Geographic Atrophy | Details |
| LP-005 | RX-001; LP-005 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Myasthenia Gravis; Peripheral Nervous System Diseases; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Amyotrophic Lateral Sclerosis | Details |
| Vensobafusp alfa | P014; KP-104 | Phase 2 Clinical | Kira Pharmaceuticals LLC | Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Thrombotic Microangiopathies; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
| Omoprubart | CAN-106 | Phase 2 Clinical | Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd | Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn | Details |
| IM-101 | IM-101 | Phase 1 Clinical | ImmunAbs Inc | Autoimmune Diseases | Details |
| ALXN-5500 | ALXN-5500 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
| RLYB-116 | RLYB-116 | Phase 1 Clinical | Rallybio Llc | Hematologic Diseases; Autoimmune Diseases; Immune System Diseases; Inflammation | Details |
| NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
| Eculizumab biosimilar (Turgut Ardika) | TUR03; TUR-03 | Phase 1 Clinical | Turgut Ardika Pty Ltd | Details | |
| EA-5 | EA5; EA-5 | Phase 1 Clinical | Shanghai Lanyi Pharmaceutical Technology Co Ltd | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Kidney Diseases | Details |
| eculizumab biosimilar(Isu Abxis) | ISU-305 | Phase 1 Clinical | Isu Abxis Co Ltd | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Avacincaptad pegol | ARC-1905; ARC-187 | Approved | Archemix Corp | Zimura, Izervay | United States | Macular Degeneration; Geographic Atrophy | Iveric Bio Inc, Astellas Pharma Inc | 2023-08-04 | Polypoidal choroidal vasculopathy; Geographic Atrophy; Macular Degeneration | Details |
| Zilucoplan Sodium | RA-101495-SC; RA-101495; ZLP-AI | Approved | Ra Pharmaceuticals Inc, Ucb Sa | ZILBRYSQ, Zilbrysq | Japan | Myasthenia Gravis | Ucb Japan Co Ltd | 2023-09-25 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases; Amyotrophic Lateral Sclerosis | Details |
| Crovalimab | RO-7112689/F01; SKY-59; RO711269; RO-711269; RG-6107; CH-7092230; RO-7092230; RO-7112689 | Approved | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | 派圣凯, Piasky | Mainland China | Hemoglobinuria, Paroxysmal | Roche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc | 2024-02-06 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Anemia, Sickle Cell | Details |
| Ravulizumab | ALXN-1210; ALXN-1810 | Approved | Alexion Pharmaceuticals Inc, Xencor Inc | Ultomiris | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2018-12-21 | Respiratory Distress Syndrome, Adult; Amyotrophic Lateral Sclerosis; Acute Lung Injury; Renal Insufficiency, Chronic; Neuromyelitis Optica; Pneumonia, Viral; Delayed Graft Function; Lupus Nephritis; Atypical Hemolytic Uremic Syndrome; Acute Kidney Injury; Myasthenia Gravis; Thrombotic Microangiopathies; Heart Diseases; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Dermatomyositis; Rejection of renal transplantation | Details |
| Eculizumab | LEX-98; h-5G1.1; 5G1-1; HAL-1 | Approved | Alexion Pharmaceuticals Inc | Soliris, 舒立瑞 | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2007-03-16 | Neuromyelitis Optica; Macular Degeneration; Kidney Failure, Chronic; Diabetes Mellitus; Urea Cycle Disorders, Inborn; Thrombocytopenia; Guillain-Barre Syndrome; Asthma; Glomerulonephritis, Membranoproliferative; Nasopharyngeal Carcinoma; Parturition; Pre-Eclampsia; Anemia, Hemolytic, Autoimmune; Myasthenia Gravis; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Atypical Hemolytic Uremic Syndrome; Rejection of organ transplantation; Vagus Nerve Diseases; Hemoglobinuria, Paroxysmal; Rejection of renal transplantation; End Stage Liver Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; HELLP Syndrome | Details |
| Pozelimab | REGN-3918 | Approved | Regeneron Pharmaceuticals Inc | VEOPOZ | United States | Protein-Losing Enteropathies | Regeneron Pharmaceuticals Inc | 2023-08-18 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies | Details |
| Eculizumab biosimilar (Amgen) | ABP-959 | Approved | Amgen Inc | BKEMV | United States | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Amgen Inc | 2024-05-28 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
| Eculizumab biosimilar (Samsung Bioepis) | SB-12; AM004; AMT-904; SB12 | Approved | Samsung Bioepis Co Ltd | Epysqli, EPYSQLI | EU | Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal | Samsung Bioepis Nl Bv | 2023-05-26 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
Product Reviews
1***32022-08-10
0People LikeI tried to express this product myself and it didn’t work, so I purchased ACRO’s products for antibody screening. The binding activity is very good and method establishment is also going very smoothly. There is also complete technical support available to help us solve any problems that arise during our experiments.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호